Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001461663 | SCV001665567 | likely benign | not provided | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001461663 | SCV002030936 | uncertain significance | not provided | 2023-01-30 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004038606 | SCV004850607 | uncertain significance | Inborn genetic diseases | 2020-10-29 | criteria provided, single submitter | clinical testing | The c.5447G>A (p.C1816Y) alteration is located in exon 27 (coding exon 26) of the C5orf42 gene. This alteration results from a G to A substitution at nucleotide position 5447, causing the cysteine (C) at amino acid position 1816 to be replaced by a tyrosine (Y). Based on data from the Genome Aggregation Database (gnomAD) database, the C5orf42 c.5447G>A alteration was observed in 0.01% (26/282708) of total alleles studied, with a frequency of 0.1% (25/24968) in the African subpopulation. This amino acid position is not conserved in available vertebrate species. The p.C1816Y alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005038230 | SCV005670411 | uncertain significance | Orofaciodigital syndrome type 6; Joubert syndrome 17 | 2024-05-11 | criteria provided, single submitter | clinical testing |